PharmaCielo Ltd.
PCLO.V
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -45.99% | -33.75% | -59.30% | 348.77% | 271.59% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -45.99% | -33.75% | -59.30% | 348.77% | 271.59% |
| Cost of Revenue | -161.99% | 43.36% | -25.52% | 35.80% | 34.32% |
| Gross Profit | 108.76% | -232.28% | -121.86% | 316.24% | 204.73% |
| SG&A Expenses | -68.76% | 72.60% | -56.85% | -22.83% | -36.23% |
| Depreciation & Amortization | -80.67% | 1.15% | -60.81% | -67.11% | -42.41% |
| Other Operating Expenses | -418.48% | -26.04% | -703.75% | -1,754.41% | 9.25% |
| Total Operating Expenses | -164.89% | 59.11% | -57.23% | -18.51% | -18.12% |
| Operating Income | 504.08% | -200.58% | 56.25% | 75.56% | 62.57% |
| Income Before Tax | 127.22% | 48.09% | 50.03% | 77.16% | 5.83% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 127.22% | 48.09% | 50.03% | 77.16% | 5.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 127.22% | 48.09% | 50.03% | 77.16% | 5.83% |
| EBIT | 504.08% | -200.58% | 56.25% | 75.56% | 62.57% |
| EBITDA | 2,019.00% | -307.51% | 46.34% | 91.70% | 57.59% |
| EPS Basic | 126.23% | 52.63% | 54.95% | 78.45% | 5.51% |
| Normalized Basic EPS | 126.32% | -108.00% | 55.07% | 45.71% | 34.18% |
| EPS Diluted | 126.23% | 52.63% | 54.95% | 78.45% | 5.51% |
| Normalized Diluted EPS | 126.32% | -108.00% | 55.07% | 45.71% | 34.18% |
| Average Basic Shares Outstanding | 7.25% | 10.74% | 10.74% | 5.43% | 0.00% |
| Average Diluted Shares Outstanding | 7.25% | 10.74% | 10.74% | 5.43% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |